Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders

References

• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376:2075–2085.
   PubMed Web of Science ®Google Scholar
• Cavo M, Pantani L, Petrucci MT, et al. Bortezomib‐thalidomide‐dexamethasone is superior to thalidomide‐dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120:9–19.
   PubMed Web of Science ®Google Scholar
• Garderet L, Iacobelli S, Moreau P, et al. Superiority of the triple combination of bortezomib‐thalidomide‐dexamethasone over the dual combination of thalidomide‐dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005‐04 randomized phase III trial from the chronic leukemia working party of the european group for blood and marrow transplantation. J Clin Oncol. 2012;30:2475–2482.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120:1589–1596.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–152.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621–1634.
   PubMed Web of Science ®Google Scholar
• Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem‐cell transplant (SWOG S0777): a randomised, open‐label, phase 3 trial. Lancet. 2017;389:519–527.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Callander NS, Alsina M, et al. Multiple myeloma, Version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014;15:230–269.
   Web of Science ®Google Scholar
• Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low‐dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120:1801–1809.
   PubMed Web of Science ®Google Scholar
• Dytfeld D, Jasielec J, Griffith KA, et al. Carfilzomib, lenalidomide, and low‐dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014;99:e162–e164.
   PubMed Web of Science ®Google Scholar
• Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib‐lenalidomide‐dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1:746–754.
   PubMed Web of Science ®Google Scholar
• Roussel M, Lauwers-Cances V, Robillard N, et al. Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, Krd consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: primary results of the intergroupe francophone du myélome (IFM) Krd phase II study. Blood. 2016;128:1142.
   Web of Science ®Google Scholar
• Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist. 2018;16:1600–1603.
   Web of Science ®Google Scholar
• Barlogie B, Mitchell A, van Rhee F, et al. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124:3043–3051.
   PubMed Web of Science ®Google Scholar
• Katodritou E, Papadaki S, Konstantinidou P, et al. Is it possible to cure myeloma without allogeneic transplantation? Transfus Apher Sci. 2016;54:63–70.
   PubMed Web of Science ®Google Scholar
• Baz R, Lin HM, Hui AM, et al. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health‐related quality of life. Support Care Cancer. 2015;23:2789–2797.
   PubMed Web of Science ®Google Scholar
• Guglielmelli T, Palumbo A. Multiple myeloma: is a shift toward continuous therapy needed to move forward? Expert Rev Hematol. 2015;8:253–256.
   PubMed Web of Science ®Google Scholar
• Dowling M, Kelly M, Meenaghan T. Multiple myeloma: managing a complex blood cancer. Br J Nurs. 2016;25:S18–S28.
   PubMedGoogle Scholar
• Delforge M, Ludwig H. How I manage the toxicities of myeloma drugs. Blood. 2017;129:2359–2367.
   PubMed Web of Science ®Google Scholar
• Assouline SE, Chang J, Cheson BD, et al. Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. Blood Cancer J. 2014;4:e251.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. cited 2018 Oct 01. Available from: https://clinicaltrials.gov/ct2/results?cond=lymphoma&term=ixazomib&cntry=&state=&city=&dist/
   Google Scholar
• Pundir S, Vu HY, Solomon VR, et al. VR23: a quinoline-sulfonyl hybrid proteasome inhibitor that selectively kills cancer via cyclin E-mediated centrosome amplification. Cancer Res. 2015;75(19):4164–4175.
   PubMed Web of Science ®Google Scholar
• Sethi G1, Ahn KS, Pandey MK, et al. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood. 2007;109(7):2727–2735.
   PubMed Web of Science ®Google Scholar
• Muchamuel T, Basler M, Aujay MA, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. MA Nat Med. 2009;15(7):781–787.
   PubMed Web of Science ®Google Scholar
• Kazi A, Ozcan S, Tecleab A, et al. Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity. J Biol Chem. 2014;289(17):11906–11915.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Singh AV, Aujay M, et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010;116(23):4906–4915.
   PubMed Web of Science ®Google Scholar
• Sanchez E, Li M, Steinberg JA, et al. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol. 2010;148(4):569–581.
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281–3290.
   PubMed Web of Science ®Google Scholar
• Boccadoro M, Morgan G, Cavenagh J, et al. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Boccadoro Cancer Cell Int. 2005;5(1):18.
   PubMed Web of Science ®Google Scholar
• Knauf W, Tapprich C, Schlag R, et al. Bortezomib-containing regimens are effective in multiple myeloma--results of a non-interventional phase IV study. Oncol Res Treat. 2015;38(4):167–173.
   PubMed Web of Science ®Google Scholar
• Muz B, Ghazarian RN, Ou M, et al. Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther. 2016;10:217–226.
   PubMed Web of Science ®Google Scholar
• Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010;70:1970–1980.
   PubMed Web of Science ®Google Scholar
• Gupta N, Zhao Y, Hui AM, et al. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. Br J Clin Pharmacol. 2015;79:789–800.
   PubMed Web of Science ®Google Scholar
• Gupta N, Diderichsen PM, Hanley MJ, et al. Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the phase III TOURMALINE-MM1 study to inform labelling. Clin Pharmacokinet. 2017;56:1355–1368.
   PubMed Web of Science ®Google Scholar
• Gupta N, Goh YT, Min CK, et al. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. J Hematol Oncol. 2015;8:103.
   PubMed Web of Science ®Google Scholar
• Gupta N, Hanley MJ, Venkatakrishnan K, et al. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. Br J Clin Pharmacol. 2016;82(3):728–738.
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Gupta N, Venkatakrishnan K, et al. A phase 1 study to assess the relative bioavailability of two capsule formulations of ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors or lymphoma. J Clin Pharmacol. 2018;58:114–121.
   PubMed Web of Science ®Google Scholar
• Gupta N, Hanley MJ, Harvey RD, et al. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis. Br J Haematol. 2016;174(5):748–759.
   PubMed Web of Science ®Google Scholar
• Gupta N, Hanley MJ, Venkatakrishnan K, et al. The effect of a high-fat meal on the pharmacokinetics of ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors or lymphoma. J Clin Pharmacol. 2016;56:1288–1296.
   PubMed Web of Science ®Google Scholar
• Millennium Pharmaceuticals Inc. NINLARO® (ixazomib) capsules, for oral use. United States prescribing information. 2016. cited 2018 Oct 1. Available from: https://www.ninlaro.com/prescribing-information.pdf
   Google Scholar
• Gupta N, Hanley MJ, Xia C, et al. Clinical pharmacology of ixazomib: the first oral proteasome inhibitor. Clin Pharmacokinet. 2018.
   Web of Science ®Google Scholar
• Takeda Pharma A/S. NINLARO European product assessment report—product information. 2016. cited 2018 Oct 1. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf
   Google Scholar
• Gupta N, Hanley MJ, Venkatakrishnan K, et al. Effects of strong CYP3A inhibition and induction on the pharmacokinetics of ixazomib, an oral proteasome inhibitor: results of drug-drug interaction studies in patients with advanced solid tumors or lymphoma and a physiologically based pharmacokinetic analysis. J Clin Pharmacol. 2018;58:180–192.
   PubMed Web of Science ®Google Scholar
• Gupta N, Zhang S, Pusalkar S, et al. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [(14)C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2018;36:407–415.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17:5311–5321.
   PubMed Web of Science ®Google Scholar
• Tian Z, Zhao JJ, Tai YT, et al. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood. 2012;120:3958–3967.
   PubMed Web of Science ®Google Scholar
• Lee EC, Fitzgerald M, Bannerman B, et al. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res. 2011;17:7313–7323.
   PubMed Web of Science ®Google Scholar
• Garcia-Gomez A, Quwaider D, Canavese M, et al. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease. Clin Cancer Res. 2014;20:1542–1554.
   PubMed Web of Science ®Google Scholar
• Al-Homsi AS, Goodyke A, McLane M, et al. Post-transplantation cyclophosphamide and ixazomib combination rescues mice subjected to experimental graft-versus-host disease and is superior to either agent alone. Biol Blood Marrow Transplant. 2017 Feb;23(2):255–261.
   PubMed Web of Science ®Google Scholar
• Boonstra PS, Polk A, Brown N, et al. A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas. Am J Hematol. 2017;92:1287–1294.
   PubMed Web of Science ®Google Scholar
• Ravi D, Beheshti A, Abermil N. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-dependent cell death in T-cell and Hodgkin lymphoma. Cancer Res. 2016;76:3319–3331.
   PubMed Web of Science ®Google Scholar
• Liu W, Chen J, Tamayo AT, et al. Preclinical efficacy and biological effects of the oral : proteasomeinhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget. 2017;9:346–360.
   PubMedGoogle Scholar
• Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014;15:1503–1512.
   PubMed Web of Science ®Google Scholar
• Gupta N, Yang H, Hanley MJ, et al. Dose and schedule selection of the oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma: clinical and model-based analyses. Target Oncol. 2017;12:643–654.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Baz R, Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014;124:1038–1046.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Buadi FK, LaPlant B, et al. Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J. 2018;8:70.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Bahlis NJ, Chng WJ, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017;130:2610–2618.
   PubMed Web of Science ®Google Scholar
• Raab MS, Podar K, Breitkreutz I. Multiple myeloma. Lancet. 2009;374:324–339.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [Internet]. Ninlaro: EPAR – product information. cited 2018 Sep 15. Available from: https://www.ema.europa.eu/documents/product-information/ninlaro-epar-product-information_en.pdf
   Google Scholar
• Richardson PG, Hofmeister CC, Rosenbaum CA, et al. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. Br J Haematol. 2018;182:231–244.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014;124:1047–1055.
   PubMed Web of Science ®Google Scholar
• Kumar SK, LaPlant BR, Reeder CB, et al. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood. 2016;128:2415–2422.
   PubMed Web of Science ®Google Scholar
• Kumar SK, LaPlant B, Roy V, et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015;5:e338.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Berdeja JG, Niesvizky R, et al. Long‐term ixazomib maintenance is tolerable and improves depth of response following ixazomib‐lenalidomide‐dexamethasone induction in patients (Pts) with previously untreated multiple myeloma (MM): phase 2 study results. Blood. 2014;124:82.
   Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Ixazomib, an investigational oral Proteasome Inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): the phase 3 tourmaline-MM1 study (NCT01564537). Blood. 2015;126:727.
   Web of Science ®Google Scholar
• Mateos MV, Masszi T, Grzasko N, et al. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica. 2017;102:1767–1775.
   PubMed Web of Science ®Google Scholar
• Leleu X, Masszi T, Bahlis NJ, et al. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Am J Hematol. 2018 May 4. Epub ahead of print. DOI:10.1002/ajh.25134.
   Web of Science ®Google Scholar
• Suzuki K, Handa H, Chou T, et al. Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. Int J Hematol. 2017;105:445–452.
   PubMed Web of Science ®Google Scholar
• Hou J, Jin J, Xu Y, et al. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China continuation study. J Hematol Oncol. 2017;10:137.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Kapoor P, Palmer JM, et al. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia. 2017 Dec 18. Epub ahead of print. DOI:10.1038/leu.2017.352.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Echeveste Gutierrez MA, Špicka I, et al. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. Haematologica. 2018;103:1518–1526.
   PubMed Web of Science ®Google Scholar
• Striha A, Ashcroft AJ, Hockaday A, et al. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials. 2018;19:169.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. cited 2018 Sep 15 Available from: https://clinicaltrials.gov/
   Google Scholar
• ClinicalTrials.gov [Internet]. Study of dexamethasone plus IXAZOMIB (MLN9708) or physicians choice of treatment in relapsed or refractory systemic light chain (AL) amyloidosis. updated 2018 Sep 7; cited 2018 Sep 7; cited 2018 Sep 7; cited 2018 Sep 7; cited 2018 Sep 20. Available from: https://clinicaltrials.gov/ct2/show/NCT01659658
   Google Scholar
• ClinicalTrials.gov [Internet]. Ixazomib citrate, lenalidomide, dexamethasone, and zoledronic acid or zoledronic acid alone after radiation therapy in treating patients with solitary plasmacytoma of bone. updated 2018 Sep 6; cited 2018 Sep 6; cited 2018 Sep 6; cited 2018 Sep 6; cited 2018 Sep 15. Available from: https://clinicaltrials.gov/ct2/show/NCT02516423
   Google Scholar
• ClinicalTrials.gov [Internet]. A two-dimensional dose-finding study of ixazomib in combination with gemcitabine and doxorubicin, followed by a phase II extension to assess the efficacy of this combination in metastatic, surgically unresectable urothelial cancer. updated 2018 Jul 20; cited 2018 Jul 20; cited 2018 Jul 20; cited 2018 Sep 20; cited 2018 Sep 15. Available from: https://clinicaltrials.gov/ct2/show/NCT02420847/
   Google Scholar
• Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130:597–605.
   PubMed Web of Science ®Google Scholar
• Smith DC, Kalebic T, Infante JR, et al. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. Invest New Drugs. 2015;33:652–663.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Meid K, Gustine JN, et al. Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in waldenström macroglobulinemia. Clin Cancer Res. 2018 15;24:3247–3252.
   PubMed Web of Science ®Google Scholar
• Kumar S, Moreau P, Hari P, et al. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol. 2017;178:571–582.
   PubMed Web of Science ®Google Scholar
• Steiner RE, Orlowski RZ, Lee HC. Acute pancreatitis associated with ixazomib in a multiple myeloma patient. Acta Haematol. 2018;139:67–70.
   PubMed Web of Science ®Google Scholar
• Alloo A, Khosravi H, Granter SR, et al. Ixazomib-induced cutaneous necrotizing vasculitis. Support Care Cancer. 2018;26:2247–2250.
   PubMed Web of Science ®Google Scholar
• Cole DC, Frishman WH. Cardiovascular complications of proteasome inhibitors used in multiple myeloma. Cardiol Rev. 2018;26:122–129.
   PubMed Web of Science ®Google Scholar
• Atallah-Yunes SA, Soe MH. Drug-induced thrombotic microangiopathy due to cumulative toxicity of ixazomib. Case Rep Hematol. 2018 Jul 3;2018:7063145. .
   PubMed Web of Science ®Google Scholar
• Passero C Jr, Dashnamoorthy R, Beheshti A, et al. The proteasome inhibitor, ixazomib, combined with novel drug combinations in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): identification of key genes and signaling pathways via a novel systems biology approach. Blood. 2015;126:2753.
   Web of Science ®Google Scholar
• Pérez-Galán P, Roué G, Villamor N, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006 Jan 1;107:257–264.
   PubMed Web of Science ®Google Scholar
• Pham L, Tamayo A, Yoshimura L, et al. Inhibition of constitutive NF-κB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171:88–95.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Budel L, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor P27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 2000;95:619–626.
   PubMed Web of Science ®Google Scholar
• Bose P, Batalo M, Holkova B, et al. Bortezomib for the treatment of non-Hodgkin’s lymphoma. Expert Opin Pharmacother. 2014;15:2443–2459.
   PubMed Web of Science ®Google Scholar
• Roue G, Perez-Galan P, Lopez-Guerra M, et al. Selective inhibition of IκB kinase sensitizes mantle cell lymphoma B cells to trail by decreasing cellular flip level. J Immunol. 2007;178:1923–1930.
   PubMed Web of Science ®Google Scholar
• Mozos A, Roué G, López-Guillermo A, et al. The expression of the endoplasmic reticulum stress sensor BIP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large B-cell lymphoma. Am J Pathol. 2011;179:2601–2610.
   PubMed Web of Science ®Google Scholar
• Chandra J, Niemer I, Gilbreath J, et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood. 1998;92:4220–4229.
   PubMed Web of Science ®Google Scholar
• Robak T, Huang H, Jin J, et al. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. Leuk Lymphoma. 2017 Jun 5:1–8. Epub ahead of print. DOI: 10.1080/10428194.2017.1321750.
   Web of Science ®Google Scholar